Oversulfated Chondroitin Sulfate is a major contaminant in Heparin associated with Adverse Clinical Events

Guerrini, M.
Beccati, D.
Shriver, Z.
Naggi, A.M.
Bisio, A.
Capila, I.
Lansing, J.
Guglieri, S.
Fraser, B.
Al-Hakim, A.
Thumbnail Image
Other Contributors
Issue Date
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
Full Citation
Oversulfated Chondroitin Sulfate is a major contaminant in Heparin associated with Adverse Clinical Events, M. Guerrini, D. Beccati, Z. Shriver, A. M. Naggi, A. Bisio, I. Capila, J. Lansing, S. Guglieri, B. Fraser, A. Al-Hakim, S. Gunay, K. Viswanathan, Z. Zhang, L. Robinson, G. Venkataraman, L. Buhse, M. Nasr, J. Woodcock, R. Langer, R. Linhardt, B. Casu, G. Torri, R. Sasisekharan, Nature Biotechnology, 26, 669-775, 2008.
Recently, certain lots of heparin have been associated with an acute, rapid onset of serious side effects indicative of an allergic-type reaction. To identify potential causes for this sudden rise in side effects, we examined lots of heparin that correlated with adverse events using orthogonal high-resolution analytical techniques. Through detailed structural analysis, the contaminant was found to contain a disaccharide repeat unit of glucuronic acid linked beta1-->3 to a beta-N-acetylgalactosamine. The disaccharide unit has an unusual sulfation pattern and is sulfated at the 2-O and 3-O positions of the glucuronic acid as well as at the 4-O and 6-O positions of the galactosamine. Given the nature of this contaminant, traditional screening tests cannot differentiate between affected and unaffected lots. Our analysis suggests effective screening methods that can be used to determine whether or not heparin lots contain the contaminant reported here.
Nature Biotechnology, 26, 669-775
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY
A full text version is available in DSpace@RPI